NCT00487175

Brief Summary

Tramadol is a largely used analgesic drug. Its role however on sensitization as occurs for example in neuropathic pain is not very well known. This protocol aims therefore at studying the effect of tramadol in a human pain model with sensitization induced by a cold stimulus, using evoked potentials to elucidate how pain is modified when tramadol is administered.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
12

participants targeted

Target at below P25 for phase_1 pain

Timeline
Completed

Started Sep 2007

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 14, 2007

Completed
1 day until next milestone

First Posted

Study publicly available on registry

June 15, 2007

Completed
3 months until next milestone

Study Start

First participant enrolled

September 1, 2007

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2007

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2008

Completed
Last Updated

March 17, 2009

Status Verified

March 1, 2009

Enrollment Period

3 months

First QC Date

June 14, 2007

Last Update Submit

March 16, 2009

Conditions

Keywords

PainsensitizationanalgesiaHealthy volunteers and pain

Outcome Measures

Primary Outcomes (1)

  • Amplitude of the evoked potential elicited by a thermal stimulus on the arm with an induced hyperalgic area

    with an induced hyperalgic area

Interventions

to compare of the analgesic of tramadol versus placebo in a pain model using evoked potentials

Eligibility Criteria

Age18 Years - 40 Years
Sexmale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Healthy men
  • Between 18 and 40 years old
  • Written consent given

You may not qualify if:

  • Concomitant medication
  • Tramadol hypersensibility
  • Excessive consumption of alcohol, tobacco, coffee, tea or toxicomania

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

CIC

Clermont-Ferrand, 63000, France

Location

MeSH Terms

Conditions

PainAgnosia

Interventions

Tramadol

Condition Hierarchy (Ancestors)

Neurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsPerceptual DisordersNeurobehavioral ManifestationsNervous System Diseases

Intervention Hierarchy (Ancestors)

CyclohexanolsHexanolsFatty AlcoholsAlcoholsOrganic ChemicalsDimethylaminesMethylaminesAminesLipids

Study Officials

  • PICKERING Gisèle, MCU-PH, pharmacology

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
OTHER

Study Record Dates

First Submitted

June 14, 2007

First Posted

June 15, 2007

Study Start

September 1, 2007

Primary Completion

December 1, 2007

Study Completion

March 1, 2008

Last Updated

March 17, 2009

Record last verified: 2009-03

Locations